Suzhou Highfine Biotech Co., Ltd. (SHE:301393)

Market Cap	6.27B +36.1%
Revenue (ttm)	558.41M +35.1%
Net Income	136.96M +17.7%
EPS	1.27 +18.6%
Shares Out	106.97M
PE Ratio	46.16
Forward PE	n/a
Dividend	0.40 (0.67%)
Ex-Dividend Date	Nov 11, 2025

Volume	3,184,346
Average Volume	2,597,661
Open	59.61
Previous Close	59.60
Day's Range	58.20 - 59.81
52-Week Range	43.53 - 63.80
Beta	0.61
RSI	64.32
Earnings Date	Apr 17, 2026

About Suzhou Highfine Biotech

Suzhou Highfine Biotech Co., Ltd. manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China. The company’s products include building blocks, protein reagents, protein crosslinkers, peptide reagents, protective amino acids, ionic liquids, PROTAC reagents, unnatural amino acids, pharmaceutical reagents of liposomes and lipid nanoparticles, nucleotide reagents, etc. Its products are used in fields of peptide, nucleotide, and pharmaceutical synthesis. The company also exports its products. S...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 428
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301393

Financial Performance

In 2024, Suzhou Highfine Biotech's revenue was 451.87 million, an increase of 16.22% compared to the previous year's 388.79 million. Earnings were 134.05 million, an increase of 35.44%.